In Vivo and In Vitro Chemotherapy Sensitivity Testing for Human Kidney Tumor Lines: A Comparative Study

Kurth, K. H.; Romijn, Johannes C.; Kappendijk, M.; Weissglas, Max; Dongen, Jan Willem Van

doi:10.1016/s0022-5347(17)41936-7

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCC models currently available are based on the subcutaneous (generally non-invasive model) or orthotopic (invasive model) implantation of human RCC cell lines into nude mice [ 9 – 11 ]. These models suffer from various limitations including that (i) they are clonal cell lines that do not recapitulate the heterogeneity of the tumors found in situ , (ii) the number of available and characterized cell lines is limited and (iii) cancer cells cultured in vitro are known to acquire genetic variability not found in the original tumors and to be sentitive to all therapeutic compounds [ 12 – 14 ], a behaviour not found in the in vivo environment.…”

Section: Introductionmentioning

confidence: 99%

Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma

Lang

Beraud²,

Béthry³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

The objective of the present work was to establish a large panel of preclinical models of human renal cell carcinoma (RCC) directly from patients, faithfully reproducing the biological features of the original tumor. RCC tissues (all stages/subtypes) were collected for 8 years from 336 patients undergoing surgery, xenografted subcutaneously in nude mice, and serially passaged into new mice up to 13 passages. Tissue samples from the primary tumor and tumors grown in mice through passages were analyzed for biological tissue stability by histopathology, mRNA profiling, von Hippel-Lindau gene sequencing, STR fingerprinting, growth characteristics and response to current therapies. Metastatic models were also established by orthotopic implantation and analyzed by imagery. We established a large panel of 30 RCC models (passage > 3, 8.9% success rate). High tumor take rate was associated with high stage and grade. Histopathologic, molecular and genetic characteristics were preserved between original tumors and case-matched xenografts. The models reproduced the sensitivity to targeted therapies observed in the clinic. Overall, these models constitute an invaluable tool for the clinical design of efficient therapies, the identification of predictive biomarkers and translational research.

show abstract